Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $40.00

Enliven Therapeutics (NASDAQ:ELVN) had its price objective increased by Robert W. Baird from $32.00 to $40.00 in a report released on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Enliven Therapeutics Stock Down 2.0 %

NASDAQ ELVN opened at $24.41 on Friday. Enliven Therapeutics has a 12-month low of $9.80 and a 12-month high of $30.03. The firm has a 50-day moving average price of $26.28 and a two-hundred day moving average price of $23.98. The company has a market capitalization of $1.15 billion, a P/E ratio of -12.85 and a beta of 1.08.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 4,250 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $22.54, for a total transaction of $95,795.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph P. Lyssikatos sold 847 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $30.00, for a total transaction of $25,410.00. Following the completion of the sale, the insider now owns 1,015,188 shares in the company, valued at approximately $30,455,640. The trade was a 0.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 152,195 shares of company stock valued at $4,091,454 in the last ninety days. 29.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC grew its stake in shares of Enliven Therapeutics by 10.6% during the third quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after buying an additional 601,611 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Enliven Therapeutics by 43.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock valued at $26,611,000 after buying an additional 313,019 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Enliven Therapeutics by 9.9% in the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock valued at $19,164,000 after buying an additional 67,813 shares during the period. State Street Corp raised its position in shares of Enliven Therapeutics by 2.9% during the third quarter. State Street Corp now owns 745,944 shares of the company’s stock worth $19,051,000 after acquiring an additional 21,018 shares during the last quarter. Finally, First Turn Management LLC lifted its stake in shares of Enliven Therapeutics by 29.5% in the third quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock worth $13,666,000 after acquiring an additional 121,849 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.